Xeljanz Safety Alert for People Who Are (1) Older, (2) Current / Past Smokers, or (3) With Cardiovascular or Cancer Risk Factors
(Posted by Tom Lamb at Drug Injury Watch)
The drug regulatory agency Health Canada issued
Law Offices of Thomas J. Lamb, P.A.
Website:
https://www.drug-injury.com/
Law Offices of Thomas J. Lamb, P.A. Blogs
Blog Authors
Latest from Law Offices of Thomas J. Lamb, P.A.
Elmiron-associated Retinopathy Risks Increased by (1) Longer Duration Use and (2) Higher Cumulative Dosage
By Tom Lamb
Elmiron Lawsuits Filed Because Drug Company Failed to Warn Before June 2020 About Elmiron-related Vision Loss Side Effects
(Posted by Tom Lamb at Drug Injury Watch)
We are handling Elmiron lawsuits for patients who have developed Elmiron-associated…
Beovu Safety Developments Presented by JAMA Ophthalmology Medical Journal in November 2021
By Tom Lamb
Meanwhile, Still Waiting for the Anticipated Beovu Label Change That Was Previewed by Novartis Back in May 2021
(Posted by Tom Lamb at Drug Injury Watch)
As the year 2021 draws to an end, we point out…
December 2021 JAK Inhibitors Drug Class Label Changes: More Warnings and Use Restrictions
By Tom Lamb
Risks of Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq
(Posted by Tom Lamb at Drug Injury Watch)
As background, in September 2021 the FDA announced that it was requiring revisions to…
Eli Lilly Attempts to Distance Olumiant From the Ominous JAK Inhibitors Drug Class Safety Issues Flagged by FDA
By Tom Lamb
Xeljanz, Rinvoq, and Olumiant Are the Three Janus Kinase (JAK) Inhibitors Getting “Black-Box” Warnings Revisions, Soon
(Posted by Tom Lamb at Drug Injury Watch)
In September 2021 the FDA announced it was requiring revisions to the “Black-Box”…
Philips Breathing Devices Recall Update: FDA Releases Explosive New Findings in November 2021
By Tom Lamb
What Philips Knew and When, What Philips Did or Did Not Do, Much More, From the FDA Form 483 Inspection Report
(Posted by Tom Lamb at Drug Injury Watch)
We occasionally go “off-topic” on this Drug Injury…
Two Padcev SJS / TEN Case Reports Published Before March 2021 Padcev Label Change About These Skin Reactions
By Tom Lamb
When Astellas Pharma First Knew About SJS / TEN Side Effects Is A Key Fact In This Still Developing Padcev Drug Safety Issue
(Posted by Tom Lamb at Drug Injury Watch)
About a month ago, on September…
Xeljanz Risks of Cardiovascular Events, as Well as Cancers, Lead to More Xeljanz Use Limitations
By Tom Lamb
October 2021 UK’s MHRA Xeljanz Action Follows September 2021 FDA Xeljanz Drug Safety Communication Update
(Posted by Tom Lamb at Drug Injury Watch)
On September 1, 2021, we posted this article, “Xeljanz: FDA Warnings Updated: There …
Imbruvica Heart-Related Side Effects Continue to Get Attention from Drug Safety Researchers
By Tom Lamb
Recent Cardiotoxicity Case Reports for Patients Using Imbruvica Alone or When Combined With Other Drugs
(Posted by Tom Lamb at Drug Injury Watch)
Just about two years ago, in mid-October 2019, we posted these two articles, “…
Xeljanz: Drug-induced Peripheral Neuropathy as Possible Xeljanz Side Effect in 2 RA Patients
By Tom Lamb
Reports of Rheumatoid Arthritis Patients on Xeljanz Experiencing Secondary Neurological Adverse Events
(Posted by Tom Lamb at Drug Injury Watch)
As we have written about previously, according to the FDA, some of the generally recognized Xeljanz side…